Adaptive Biotechnologies Corp — Director's Dealing 2020

Feb 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-02-13

Reporting Person: ROBINS CHAD M (Director, CEO and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-13	Common Stock	M	11120	$0.33	Acquired	1889300	Direct
2020-02-13	Common Stock	S	11120	$31.56	Disposed	1878180	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-13	Stock Option (Right to Buy)	$0.33	M	11120	Disposed	2021-12-20	Common Stock (11120)	Direct
2020-02-13	Stock Option (Right to Buy)	$31.71	A	300000	Acquired	2030-02-13	Common Stock (300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	500000	Indirect
Common Stock	350000	Indirect

Footnotes

F1: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.02 to 31.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4: The options are fully vested and exercisable.

F5: The options will vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.